000 02754nam  2200325za 4500
0019.837289
003CaOODSP
00520221107151113
007cr |||||||||||
008160629s2017    onca|  #ob   f000 0 eng d
040 |aCaOODSP|beng
043 |an-cn---
0861 |aH82-28/2017E-PDF
1101 |aCanada. |bHealth Canada.
24510|aProtecting Canadians from excessive drug prices |h[electronic resource] : |bconsulting on proposed amendements to the Patented Medicines Regulations.
24630|aConsulting on proposed amendements to the Patented Medicines Regulations
260 |a[Ottawa] : |bHealth Canada, |c2017.
300 |a16 p. : |bcol. ill.
500 |aCover title.
500 |a"This consultation period is 6 weeks, running from May 16, 2017 to June 28, 2017"--p. 5.
500 |aIssued also in French under title: Protéger les Canadiens des prix excessifs des médicaments : consultation sur les modificaations proposées au Règlement sur les médicaments brevetés.
504 |aIncludes bibliographical references.
5200 |a"In January 2016, federal, provincial and territorial Ministers agreed to work together to improve the affordability, accessibility and appropriate use of prescription drugs to better meet health care system needs. ... This important work includes reducing the cost of patented drugs through the modernization of the pricing framework under the Patented Medicine Prices Review Board (PMRPB). Under the authority of the Patent Act and through the Patented Medicines Regulations (“Regulations”), the Government of Canada regulates the prices of patented medicines in Canada to ensure that prices are not excessive. Despite significant changes in the pharmaceutical market, the regulations have not been substantively changed in over two decades. Health Canada is consulting stakeholders and interested members of the public on proposed amendments to the Regulations, to equip the PMPRB with more relevant and effective regulatory tools to better protect Canadians from excessive prices for patented drugs. ... Feedback received on or before June 28th, 2017, will be considered in developing a regulatory proposal under the Patent Act to protect Canadians from excessive drug prices. A summary of comments will be published in the RIAS statement at Canada Gazette, Part I"--p. 3 and p. 16.
69207|2gccst|aDrugs
69207|2gccst|aPrice regulation
69207|2gccst|aReform
69207|2gccst|aConsultations
7101 |aCanada. |bPatented Medicine Prices Review Board.
77508|tProtéger les Canadiens des prix excessifs des médicaments |w(CaOODSP)9.837292
85640|qPDF|s1.18 MB|uhttps://publications.gc.ca/collections/collection_2017/sc-hc/H82-28-2017-eng.pdf